Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I/II, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination With Cemiplimab in Patients with Solid Tumors, including Pancreatic Cancer (GLIMMER-01)

Summary

The purpose of this phase I/II trial is to evaluate the safety and tolerability of E-602 as a monotherapy and E-602 in combination with cemiplimab in patients with solid tumors, including pancreatic cancer.

General Information

NCT#: NCT05259696
Study ID: PAL-E602-001
Trial Phase: Phase I/II

Trial Sponsor: Palleon Pharmaceuticals, Inc.
Therapies Used in This Trial: Pembrolizumab, E-602

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search